Filing Analysis
Kairos Pharma, Ltd. issued a press release on June 4, 2026, summarizing the company's achievements for the first half of 2026 and outlining expected milestones for the remainder of the year.
📋 Key Facts
- The filing date is June 4, 2026.
- The company provided a summary of H1 2026 achievements.
- The company outlined key milestones expected by the end of 2026.
- The information was furnished as Exhibit 99.1 and is not deemed 'filed' under Section 18 of the Exchange Act.
Kairos Pharma, Ltd. issued a new investor presentation on May 18, 2026, for use at the LD Micro Invitational XVI conference. CEO John Yu will present updates regarding the company's clinical programs and partnering activities.
📋 Key Facts
- The report was filed on May 18, 2026, coinciding with the LD Micro Invitational XVI in Los Angeles.
- CEO John Yu is scheduled to provide updates on clinical programs and partnering activities.
- The investor presentation is furnished as Exhibit 99.1.
- The company is an emerging growth company listed on the NYSE American under the symbol KAPA.
Kairos Pharma entered into a binding term sheet to acquire 100% of the worldwide rights to CL-273, a pan EGFR small molecule inhibitor for lung cancer, from Celyn Therapeutics. The transaction involves significant equity issuance and future milestone payments.
🚩 Red Flags
- Significant dilution of 16.5% for existing shareholders.
- Substantial future cash/equity obligation of $15 million upon regulatory filing.
- The asset CL-273 is noted as being developed by Eilean Therapeutics, suggesting a potentially complex chain of ownership or licensing with Celyn.
📋 Key Facts
- Acquisition of 100% worldwide rights to CL-273, including IP, manufacturing, and regulatory rights.
- Consideration includes issuing shares representing 16.5% of the Company on a fully diluted basis.
- A $15 million milestone payment is due upon FDA NDA/BLA submission, payable in cash and shares.
- A 2% royalty on U.S. net revenues will be paid for the life of the applicable IP.
- Closing is subject to shareholder approval and potential NYSE American approval.
Kairos Pharma, Ltd. has entered into a letter of intent with Celyn Therapeutics, Inc. to acquire worldwide rights to two clinical-stage oncology assets targeting non-small cell lung cancers (NSCLC). The assets include CL-273, a pre-IND pan-EGFR inhibitor, and CL-741, a Phase 1-ready c-MET kinase inhibitor.
🚩 Red Flags
- The filing does not disclose the financial terms, purchase price, or potential dilution associated with the acquisition.
- A letter of intent is generally non-binding, and there is no guarantee the transaction will close on the proposed terms.
📋 Key Facts
- Letter of Intent (LOI) signed on February 26, 2026, with Celyn Therapeutics, Inc.
- Acquisition targets worldwide rights to two oncology assets: CL-273 and CL-741.
- CL-273 is described as a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor.
- CL-741 is described as a Phase 1-ready, orally available type IIb c-MET kinase inhibitor.
- Both assets are specifically designed to target non-small cell lung cancers (NSCLC).